IMPL

Impel Pharmaceuticals Announces Filing of Voluntary Chapter 11 Cases and Signing of "Stalking Horse" Agreement to Facilitate Sale

Retrieved on: 
Wednesday, December 20, 2023

SEATTLE, Dec. 19, 2023 /PRNewswire/ -- Impel Pharmaceuticals Inc. (OTCQX: IMPL) ("Impel" or "the Company"), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced that it is pursuing a sale of the Company and has entered into an agreement with JN BIDCO LLC to serve as the "stalking horse" bidder to acquire the Company and its assets.

Key Points: 
  • To facilitate an orderly sale process, the Company has filed voluntary petitions to commence chapter 11 proceedings in the U.S. Bankruptcy Court for the Northern District of Texas (the "Court"), which will provide interested parties the opportunity to submit higher and better offers.
  • Impel's Interim President & Chief Executive Officer, Len Paolillo, said: "After carefully reviewing all available strategic options with our advisors, Impel made the decision to pursue a sale through an in-court restructuring process.
  • Impel intends to continue operating as usual throughout the court-supervised sale process, including providing wages and benefits to employees.
  • Impel seeks to complete the sale process in the first quarter of 2024, with any sale subject to Court approval.

Impel Pharmaceuticals Announces Exploration of Strategic Alternatives

Retrieved on: 
Thursday, October 5, 2023

SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL) (“Impel” or “the Company”), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced that it has initiated an exploration of strategic alternatives.

Key Points: 
  • SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL) (“Impel” or “the Company”), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced that it has initiated an exploration of strategic alternatives.
  • As the Company explores strategic options, Impel continues to provide full commercial support behind Trudhesa, including Trudhesa Direct access support.
  • There can be no assurance that this process will result in the Company pursuing or consummating any particular transaction or other strategic outcome.
  • However, if the Company is unable to complete a transaction, it may be necessary to seek additional financing or other alternatives for restructuring and resolving its liabilities.

Impel Pharmaceuticals to Present New Real-World Data for Trudhesa® at the 65th Annual Scientific Meeting of the American Headache Society

Retrieved on: 
Thursday, June 15, 2023

SEATTLE, June 15, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will present new real-world data adding to the growing body of evidence supporting Trudhesa® (dihydroergotamine mesylate [DHE]) nasal spray (0.725 mg per spray) as an effective acute therapy for migraine management. The findings will be featured in two poster presentations during the 65th Annual Scientific Meeting of the American Headache Society (AHS), taking place June 15-18, 2023, in Austin, Texas.

Key Points: 
  • The findings will be featured in two poster presentations during the 65th Annual Scientific Meeting of the American Headache Society (AHS), taking place June 15-18, 2023, in Austin, Texas.
  • Importantly, an increase in antinausea medications was not observed following Trudhesa use, whereas these medications are commonly used with DHE administered intravenously.
  • “DHE has an established safety and efficacy profile, often providing long-lasting relief for even the toughest of migraine attacks.
  • However, until Trudhesa, nasal delivery options couldn’t reach the upper nasal space, where DHE can be rapidly absorbed,” said Zubair Ahmed, M.D., a headache specialist and neurologist at the Cleveland Clinic.

Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Friday, May 12, 2023

SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the first quarter ended March 31, 2023 and provided a business update.

Key Points: 
  • ET
    SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the first quarter ended March 31, 2023 and provided a business update.
  • ET today to discuss the first quarter 2023 financial results and provide a corporate and business update.
  • A live webcast of the event will be available on the Investors section of the Impel Pharmaceuticals website at https://investors.impelpharma.com/ .
  • A replay of the webcast and accompanying slides will be available on the Impel Pharmaceuticals website following the event.

Impel Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer

Retrieved on: 
Wednesday, May 10, 2023

SEATTLE, May 10, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Michael W. Kalb, CPA, as Chief Financial Officer, effective May 10, 2023.

Key Points: 
  • SEATTLE, May 10, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Michael W. Kalb, CPA, as Chief Financial Officer, effective May 10, 2023.
  • “Michael brings an outstanding track record of executive leadership in finance, capital raising, business development and operations management to Impel Pharmaceuticals,” said Adrian Adams, Chairman of the Board and Chief Executive Officer of Impel Pharmaceuticals.
  • Prior to joining Impel Pharmaceuticals, he was Executive Vice President & Chief Financial Officer of CinCor Pharma, Inc., where he played an integral role in the company’s recent acquisition by AstraZeneca for up to $1.8 billion.
  • Mr. Kalb added, “I am thrilled to join Impel’s accomplished leadership team at such an important time in the Company’s evolution.

Impel Pharmaceuticals to Report First Quarter 2023 Financial Results on Friday, May 12, 2023

Retrieved on: 
Friday, May 5, 2023

SEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, May 12, 2023, at 8:30 a.m.

Key Points: 
  • SEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, May 12, 2023, at 8:30 a.m.
  • ET to report its first quarter 2023 financial results and provide a business update.
  • A live webcast of the event will be available on the Investors section of the Impel Pharmaceuticals website at https://investors.impelpharma.com/ .
  • A replay of the webcast and accompanying slides will be available on the Impel Pharmaceuticals website following the event.

Impel Pharmaceuticals Presents New Data at AAN 2023 Suggesting Trudhesa® Nasal Spray is Safe to Use When Co-Administered With Commonly Prescribed Migraine Medications

Retrieved on: 
Wednesday, April 26, 2023

SEATTLE, April 26, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today presented results from the first-ever pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of potential drug-drug interactions (DDIs) between Trudhesa® (dihydroergotamine [DHE] mesylate) nasal spray (0.725 mg per spray) and orally administered gepant medications.

Key Points: 
  • The analysis being presented suggests that no DDIs of clinical concern are theoretically predicted if Trudhesa and gepants are co-administered within recommended clinical doses.
  • Additionally, while first-pass metabolism may limit the bioavailability of orally administered drugs, since Trudhesa is administered via the upper nasal space, it bypasses the gastrointestinal (GI) and hepatic first-pass metabolism.
  • “These data suggest that Trudhesa used with some oral CGRP (calcitonin gene-related peptide) acute medications may be a safe option that warrants further study.
  • These analyses shed some light on the potential safety profile of Trudhesa when prescribed concomitantly with certain other widely used migraine therapeutics,” said Sheena Aurora, M.D., Vice President Medical Affairs, Impel Pharmaceuticals.

Impel Pharmaceuticals Announces Appointment of Darren Cline to the Board of Directors

Retrieved on: 
Wednesday, April 12, 2023

SEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Darren Cline to the Board of Directors.

Key Points: 
  • SEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Darren Cline to the Board of Directors.
  • The Company also announced the departure of H. Stewart Parker, with both changes to the Board effective immediately.
  • "It is my pleasure to welcome Darren to the Impel Board of Directors,” said Adrian Adams, Chairman of the Board and Chief Executive Officer of Impel Pharmaceuticals.
  • Mr. Cline currently serves on the board of directors of Pliant Therapeutics and Pyxis Oncology.

Impel Pharmaceuticals to Present Data on Trudhesa® Nasal Spray for Treatment of Acute Migraine at 2023 American Academy of Neurology Annual Meeting

Retrieved on: 
Tuesday, April 11, 2023

SEATTLE, April 11, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, announced today that four Trudhesa® (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) abstracts have been selected to be presented at the upcoming American Academy of Neurology (AAN) Annual Meeting taking place in Boston, MA, April 22-27, 2023.

Key Points: 
  • SEATTLE, April 11, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, announced today that four Trudhesa® (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) abstracts have been selected to be presented at the upcoming American Academy of Neurology (AAN) Annual Meeting taking place in Boston, MA, April 22-27, 2023.
  • The Trudhesa posters to be presented are as follows:
    A Cross-Sectional Survey of Prevailing Opinions from Headache Specialists Regarding Status Migrainosus Management; ( Poster 12-001; Session 11 )
    Assessment of the Potential for Drug–Drug Interactions Between INP104 and Gepants for Migraine Management Using a Model-based Approach ( Poster 12-008; Session 12 )
    Safety and Efficacy of Concomitant Erenumab and INP104 Use from the Phase 3 STOP 301 Study in Migraine Patients ( Poster 12-002; Session 13 )
    Safety of Concomitant Triptan and INP104 Use from the Phase 3 STOP 301 Study in Migraine Patients ( Poster 12-011; Session 14 )

Cellarity Strengthens Executive Leadership Team

Retrieved on: 
Tuesday, April 11, 2023

The Cellarity platform uncovers novel actionable biology and creates non-intuitive drug candidates to address a vast array of diseases, even those with either limited or unknown targets.

Key Points: 
  • The Cellarity platform uncovers novel actionable biology and creates non-intuitive drug candidates to address a vast array of diseases, even those with either limited or unknown targets.
  • These new leadership appointments will allow Cellarity to accelerate development of its platform and progress its pipeline programs towards the clinic.
  • “Their appointments are a great complement to the already well experienced senior leadership team which includes Parul Doshi, recently promoted to Chief Data Officer.
  • Prior to joining Cellarity, he was previously Executive Medical Director in Clinical Development at Forma Therapeutics (acquired by Novo Nordisk) where he led their flagship sickle cell disease program.